Hyperphosphatemia with elevated serum PTH and FGF23, reduced 1,25(OH)(2)D and normal FGF7 concentrations characterize patients with CKD

BACKGROUND: Hyperphosphatemia confers adverse cardiovascular outcomes, and commonly occurs in late-stage CKD. Fibroblast growth factor 7 (FGF7) is a phosphaturic peptide which decreases renal phosphate transport in vitro and in vivo. Serum FGF7 concentrations are reduced in hyperphosphatemic patient...

Descripción completa

Detalles Bibliográficos
Autores principales: Kritmetapak, Kittrawee, Losbanos, Louis, Berent, Taylor E., Ashrafzadeh-Kian, Susan L., Algeciras-Schimnich, Alicia, Hines, Jolaine M., Singh, Ravinder J., Kumar, Rajiv
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8011073/
https://www.ncbi.nlm.nih.gov/pubmed/33784965
http://dx.doi.org/10.1186/s12882-021-02311-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8011073/
https://www.ncbi.nlm.nih.gov/pubmed/33784965
http://dx.doi.org/10.1186/s12882-021-02311-3

Ejemplares similares